Protocol 21427/BAY0903201: ROAR: Riociguat Users Registry
07/13/2021 - 02/28/2024 (PI)Bayer HealthCare Pharmaceuticals
Protocol # STERIO-SCD, A Phase lib Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases
03/20/2018 - 09/19/2023 (Subcontract PI)University of Pittsburgh Bayer HealthCare
Protocol # 402-C-1602, An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension.
07/27/2017 - 07/26/2022 (PI)Reata Pharmaceuticals, Inc.
Protocol #APD811-303: A Study Evaluating the Long-Term Efficacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
02/06/2019 - 02/06/2022 (PI)United Therapeutics Corporation
Assessing the effectiveness of anti-sickling agents for sickle hemoglobin and red blood cells
02/01/2016 - 01/31/2022 (PI)The General Hospital Corporation d/b/a Massachusetts General Hospital
An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension
12/12/2014 - 12/31/2021 (PI)Arena Pharmaceuticals Inc.
A StuDy eVAluatiNg the EfficaCy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
11/30/2018 - 11/30/2021 (PI)United Therapeutics Corporation
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
10/12/2016 - 10/11/2021 (PI)Reata Pharmaceuticals, Inc.
The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo
07/15/2015 - 07/14/2021 (PI)Actelion Pharmaceuticals, Ltd.
Neutrophil Elastase as a Biomarker for Neutrophil-mediated Pathbiology in Sickle Cell Disease
12/21/2015 - 06/20/2021 (Subcontract PI)Children's Hospital, Oakland Bayer HealthCare
Showing 10 of 31 results.
Show All Results